Clinical Trial Update: First Patient Dosed in Phase 1/2a Trial of AGLE-102 in DEB
The first patient has been dosed in a Phase 1/2a clinical study evaluating AGLE-102 for the treatment of dystrophic epidermolysis bullosa (DEB), Aegle Therapeutics Corp. reports. AGLE-102 is an investigational product comprised of extracellular vesicles isolated from allogeneic stem cells using Aegle’s proprietary methods. AGLE-102 is a native composite of cell-derived nanoparticles that contain active biomolecules […]